Thermostable foot-and-mouth disease virus as a vaccine candidate for endemic countries: A perspective

Vaccine

Volumn 27, Issue 16, 2009, Pages 2199-2201

  Hegde, Nagendra R ^a   Maddur, Mohan S ^b,c   Rao, Pavuluri Panduranga ^a   Kaveri, Srini V ^b,c,d   Bayry, Jagadeesh ^b,c,d  

^a Bharat Biotech Foundation   (India)

^b INSERM   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Foot and mouth disease; Foot and mouth disease virus; Thermostability; Vaccine

Indexed keywords

AMINO ACID; EPITOPE; FOOT AND MOUTH DISEASE VACCINE; FORMALDEHYDE; RECOMBINANT DNA; VIRUS PROTEIN; VIRUS VECTOR;

AFRICA; ASIA; BIOINFORMATICS; EDITORIAL; ENDEMIC DISEASE; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; IMMUNITY; IMMUNOGENICITY; MEDICAL RESEARCH; MUTATION; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; SOUTH AMERICA; THERMOSTABILITY; VACCINATION;

ANIMALS; FOOT-AND-MOUTH DISEASE VIRUS; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 62149085925     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.032     Document Type: Editorial

References (30)

1. Grubman M.J., and Baxt B. Foot-and-mouth disease. Clin Microbiol Rev 17 2 (2004) 465-493
2. Kitching P., Hammond J., Jeggo M., Charleston B., Paton D., Rodriguez L., et al. Global FMD control-is it an option?. Vaccine 25 30 (2007) 5660-5664
3. Balamurugan V., Renji R., Venkatesh G., Reddy G.R., Nair S.P., Ganesh K., et al. Protective immune response against foot-and-mouth disease virus challenge in guinea pigs vaccinated with recombinant P1 polyprotein expressed in Pichia pastoris. Arch Virol 150 5 (2005) 967-979
4. Wang X., Zhang X., Kang Y., Jin H., Du X., Zhao G., et al. Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus. Vaccine 26 40 (2008) 5135-5144
5. Su B., Wang J., Wang X., Jin H., Zhao G., Ding Z., et al. The effects of IL-6 and TNF-alpha as molecular adjuvants on immune responses to FMDV and maturation of dendritic cells by DNA vaccination. Vaccine 26 40 (2008) 5111-5122
6. Cubillos C., de la Torre B.G., Jakab A., Clementi G., Borras E., Barcena J., et al. Enhanced mucosal immunoglobulin A response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide. J Virol 82 14 (2008) 7223-7230
7. Li Y., Stirling C.M., Denyer M.S., Hamblin P., Hutchings G., Takamatsu H.H., et al. Dramatic improvement in FMD DNA vaccine efficacy and cross-serotype antibody induction in pigs following a protein boost. Vaccine 26 21 (2008) 2647-2656
8. Choudary S., Ravikumar P., Ashok Kumar C., Suryanarayana V.V., and Reddy G.R. Enhanced immune response of DNA vaccine (VP1-pCDNA) adsorbed on cationic PLG for foot and mouth disease in guinea pigs. Virus Genes 37 1 (2008) 81-87
9. Yang B., Lan X., Li X., Yin X., Li B., Han X., et al. A novel bi-functional DNA vaccine expressing VP1 protein and producing antisense RNA targeted to 5′UTR of foot-and-mouth disease virus can induce both rapid inhibitory effect and specific immune response in mice. Vaccine 26 43 (2008) 5477-5483
10. Greenwood D.L., Dynon K., Kalkanidis M., Xiang S., Plebanski M., and Scheerlinck J.P. Vaccination against foot-and-mouth disease virus using peptides conjugated to nano-beads. Vaccine 26 22 (2008) 2706-2713
11. Du Y., Jiang P., Li Y., He H., Jiang W., Wang X., et al. Immune responses of two recombinant adenoviruses expressing VP1 antigens of FMDV fused with porcine granulocyte macrophage colony-stimulating factor. Vaccine 25 49 (2007) 8209-8219
12. Mateo R., Luna E., Rincon V., and Mateu M.G. Engineering viable foot-and-mouth disease viruses with increased thermostability as a step in the development of improved vaccines. J Virol 82 24 (2008) 12232-12240
13. Doel T.R. FMD vaccines. Virus Res 91 1 (2003) 81-99
14. Goris N., Merkelbach-Peters P., Diev V.I., Verloo D., Zakharov V.M., Kraft H.P., et al. European Pharmacopoeia foot-and-mouth disease vaccine potency testing in cattle: between test variability and its consequences. Vaccine 25 17 (2007) 3373-3379
15. Knowles N.J., Samuel A.R., Davies P.R., Midgley R.J., and Valarcher J.F. Pandemic strain of foot-and-mouth disease virus serotype O. Emerg Infect Dis 11 12 (2005) 1887-1893
16. Patil P.K., Bayry J., Nair S.P., Gopalakrishna S., Sajjanar C.M., Misra L.D., et al. Early antibody responses of cattle for foot-and-mouth disease quadrivalent double oil emulsion vaccine. Vet Microbiol 87 2 (2002) 103-109
17. Jamal S.M., Bouma A., van den Broek J., Stegeman A., Chenard G., and Dekker A. Foot-and-mouth disease vaccine potency testing: the influence of serotype, type of adjuvant, valency, fractionation method, and virus culture on the dose-response curve in cattle. Vaccine 26 50 (2008) 6317-6321
18. Mateo R., Diaz A., Baranowski E., and Mateu M.G. Complete alanine scanning of intersubunit interfaces in a foot-and-mouth disease virus capsid reveals critical contributions of many side chains to particle stability and viral function. J Biol Chem 278 42 (2003) 41019-41027
19. Cox S.J., Voyce C., Parida S., Reid S.M., Hamblin P.A., Hutchings G., et al. Effect of emergency FMD vaccine antigen payload on protection, sub-clinical infection and persistence following direct contact challenge of cattle. Vaccine 24 16 (2006) 3184-3190
20. Mateo R., Luna E., and Mateu M.G. Thermostable variants are not generally represented in foot-and-mouth disease virus quasispecies. J Gen Virol 88 Pt 3 (2007) 859-864
21. Sa-Carvalho D., Rieder E., Baxt B., Rodarte R., Tanuri A., and Mason P.W. Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J Virol 71 7 (1997) 5115-5123
22. Fry E.E., Lea S.M., Jackson T., Newman J.W., Ellard F.M., Blakemore W.E., et al. The structure and function of a foot-and-mouth disease virus-oligosaccharide receptor complex. EMBO J 18 3 (1999) 543-554
23. Jackson A.L., O'Neill H., Maree F., Blignaut B., Carrillo C., Rodriguez L., et al. Mosaic structure of foot-and-mouth disease virus genomes. J Gen Virol 88 Pt 2 (2007) 487-492
24. Scodeller E.A., Lebendiker M.A., Dubra M.S., Crespo O.A., Basarab O., La Torre J.L., et al. Inactivation of foot-and-mouth disease virus vaccine strains by activation of virus-associated endonuclease. J Gen Virol 65 Pt 9 (1984) 1567-1573
25. Amadori M., Barei S., Melegari M., and Panina G.F. Safety and efficacy of foot-and-mouth disease vaccines containing endonuclease-inactivated virions. Vaccine 5 3 (1987) 219-222
26. Patil P.K., Suryanarayana V., Bist P., Bayry J., and Natarajan C. Integrity of GH-loop of foot-and-mouth disease virus during virus inactivation: detection by epitope specific antibodies. Vaccine 20 7-8 (2002) 1163-1168
27. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5 7 (2007) 505-517
28. Bayry J., Tchilian E.Z., Davies M.N., Forbes E.K., Draper S.J., Kaveri S.V., et al. In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc Natl Acad Sci USA 105 29 (2008) 10221-10226
29. Roeder P.L. The animal story. BMJ 331 7527 (2005) 1262-1264
30. Doel T.R. Natural and vaccine induced immunity to FMD. Curr Top Microbiol Immunol 288 (2005) 103-131